{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:42:37Z","timestamp":1785811357120,"version":"3.56.0"},"reference-count":12,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0372-4","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T01:15:34Z","timestamp":1528938934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment"],"prefix":"10.1136","volume":"6","author":[{"given":"L\u00e9a","family":"Paolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Crou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Labarri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-3860","authenticated-orcid":false,"given":"Jos\u00e9","family":"Hureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"372_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL Jr, Gaughan EM. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer. 2016;4:94.","journal-title":"J Immunother Cancer"},{"key":"372_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","volume":"2","author":"KC Suozzi","year":"2016","unstructured":"Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2:264\u20138.","journal-title":"JAAD Case Rep"},{"key":"372_CR3","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"FX Danlos","year":"2016","unstructured":"Danlos FX, Pages C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, et al. Nivolumab-induced Sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:e133\u20136.","journal-title":"Chest"},{"key":"372_CR4","doi-asserted-by":"crossref","unstructured":"Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176:1060\u20133.","DOI":"10.1111\/bjd.14808"},{"key":"372_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"372_CR6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","volume":"27","author":"S Cousin","year":"2016","unstructured":"Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178\u20139.","journal-title":"Ann Oncol"},{"key":"372_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016;2:290\u20133.","journal-title":"JAAD Case Rep"},{"key":"372_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","volume":"3","author":"MR Birnbaum","year":"2017","unstructured":"Birnbaum MR, Ma MW, Fleisig S, Packer S, Amin BD, Jacobson M, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3:208\u201311.","journal-title":"JAAD Case Rep"},{"key":"372_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","volume":"190","author":"NA Braun","year":"2014","unstructured":"Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190:560\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"372_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MOH.0000000000000301","volume":"24","author":"P Sakthivel","year":"2017","unstructured":"Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24:59\u201365.","journal-title":"Curr Opin Hematol"},{"key":"372_CR12","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/ncomms6997","volume":"6","author":"AR Khan","year":"2015","unstructured":"Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6:5997.","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0372-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0372-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0372-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:38Z","timestamp":1601055818000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0372-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0372-4","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Samples were collected after informed consent of patients (authorisation number CB2012\/09).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}